StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a report released on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright decreased their target price on Trevena from $225.00 to $125.00 and set a “buy” rating for the company in a research report on Thursday, May 16th.
Check Out Our Latest Report on Trevena
Trevena Stock Down 2.4 %
Trevena (NASDAQ:TRVN – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($9.25) by $9.02. The company had revenue of $0.33 million during the quarter. On average, research analysts anticipate that Trevena will post -32.25 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new stake in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent reporting period. Institutional investors own 13.56% of the company’s stock.
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading
- Five stocks we like better than Trevena
- How to Read Stock Charts for Beginners
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Profitably Trade Stocks at 52-Week Highs
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.